A fixed combination of grazoprevir and elbasvir for the treatment of hepatitis c virus infection

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-HPS-065
• By: YOO, Bong-Kyu (College of Pharmacy, Gachon University, Inchon, Korea, Republic Of)
• Co-author(s): Bong-Kyu Yoo:
  Min-Gu Kang: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
  Min-Jung Kang: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
  Eun Kyung Choi: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
  Eunhee Ji: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
  
• Abstract:

  Background

  There is a need to evaluate the efficacy and safety of the new drug, a fixed combination of grazoprevir and elbasvir (GE), in the treatment of hepatitis C virus (HCV) infection.

  Purpose

  The study aimed to systematically analyze pivotal Phase III clinical studies of GE with regard to the efficacy and safety of the new drug.

  Methods

  Data of..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login